CLARITIN REDITABS Drug Patent Profile

Which patents cover Claritin Reditabs, and what generic alternatives are available?

Claritin Reditabs is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.

The generic ingredient in CLARITIN REDITABS is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin Reditabs

A generic version of CLARITIN REDITABS was approved as loratadine by PLD ACQUISITIONS LLC on January 21^st, 2003.

Summary for CLARITIN REDITABS

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	148
Clinical Trials:	3
Patent Applications:	3,933
DailyMed Link:	CLARITIN REDITABS at DailyMed

Recent Clinical Trials for CLARITIN REDITABS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.
Ranbaxy Laboratories Limited	N/A

See all CLARITIN REDITABS clinical trials

US Patents and Regulatory Information for CLARITIN REDITABS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021993-001	Dec 12, 2006		OTC	Yes	Yes
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-002	Nov 27, 2002		OTC	Yes	Yes

Expired US Patents for CLARITIN REDITABS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-002	Nov 27, 2002
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-002	Nov 27, 2002

International Patents for CLARITIN REDITABS

See the table below for patents covering CLARITIN REDITABS around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	55797	Fluoro substituted benzocycloheptapyridine compounds compositions and methods of use as antihistaminic compounds
Hungary	194864	PROCESS FOR PRODUCTION OF 8-CHLOR-6,11-DIHYDRO-11-(4-PIPERIDILIDENE)-5H-BENZO (5,6)-CYCLO-HEPTA (1,2-B) PYRIDINE AND ITS SALTS
Spain	554898
Australia	5737486
Argentina	241463	PROCEDIMIENTO PARA PREPARAR AZA DERIVADOS DE PIPERILIDEN CICLOHEPTENOS, Y PROCEDIMIENTO PARA PREPARAR COMPOSICIONES FARMACEUTICAS UTILES. (PROCESS FOR PREPARING PIPERIDYLIDENE DIHYDRODIBENZO(A,D)CYCLOHEPTENES AND AZA DERIVATIVES THEREOF, COMPOUNDS OBTAINED BY SUCH PROCESS AND THE USE OF SUCH COMPOUNDS FOR PREPARING USEFUL PHARMACEUTICAL COMPOSITIONS)
Australia	5702690
Singapore	69193

Supplementary Protection Certificates for CLARITIN REDITABS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

CLARITIN REDITABS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Claritin RediTabs

Market Overview

Claritin RediTabs, a product of the Claritin brand, is a significant player in the global antihistamine market, particularly in the segment of non-drowsy allergy relief medications. Here’s a detailed look at the market dynamics and financial trajectory of Claritin RediTabs.

Market Size and Forecast

The Claritin market, which includes Claritin RediTabs, was valued at USD 0.16 billion in 2023 and is projected to reach USD 0.26 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.67% during the forecast period of 2024-2031[1].

Global Market Drivers

Several factors drive the growth of the Claritin RediTabs market:

Product Innovation

Continuous research and development have led to the introduction of novel formulations, such as extended-release variants and combination medicines. These innovations enhance convenience and efficacy, appealing to consumers seeking better allergy relief solutions[1].

Alterations in Lifestyle Factors

Urbanization and increased exposure to allergens like pollen, dust mites, and pet dander have resulted in a higher demand for allergy treatments. This shift in lifestyle factors contributes significantly to the market growth[1].

Seasonal Demand

Seasonal allergies, particularly during spring and autumn, drive up the demand for allergy relief medications like Claritin RediTabs. This seasonal variability is a key driver of sales[1].

Promotions and Marketing

Effective marketing strategies, including commercials and promotional campaigns, enhance brand awareness and stimulate sales. Strong marketing efforts by major players like Bayer AG, the manufacturer of Claritin, play a crucial role in market growth[1].

Global Expansion

The expansion of Claritin into new markets and regions increases its consumer base and potential revenue. This geographical expansion is vital for sustaining market growth[1].

Global Market Restraints

Despite the growth drivers, several factors act as restraints to the Claritin RediTabs market:

Competition from Generic Brands

The presence of generic loratadine products at lower prices can constrain the market share of branded Claritin RediTabs, impacting profitability[1].

Market Saturation

The presence of numerous established antihistamine medicines can lead to market saturation, complicating Claritin’s efforts to sustain growth[1].

Adverse Effects and Consumer Reservations

Some consumers may be reluctant to use antihistamines due to possible side effects, such as drowsiness (although Claritin is non-drowsy), which can hinder widespread acceptance[1].

Regulatory Challenges

Changes in legislation or constraints on advertising and marketing can influence the promotion and sale of Claritin RediTabs[1].

Economic Factors

Economic recessions or fluctuations can impact consumer expenditure on healthcare products, including allergy medications[1].

Changes in Consumer Preferences

Increasing trends towards natural and holistic health treatments may prompt customers to seek alternatives to traditional drugs like Claritin RediTabs[1].

Market Segmentation Analysis

The global Claritin market, including Claritin RediTabs, is segmented based on product type, distribution channel, formulation, and geography.

Distribution Channels

Online retail has emerged as a dynamic sub-segment, experiencing significant growth due to increasing digital penetration and the convenience of home delivery. Health stores also play a crucial role, catering to health-conscious consumers who seek specialized products and personalized service[1].

Geographical Segmentation

The market is primarily categorized into five key geographical sub-segments: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States and Canada, has significant market penetration due to strong brand recognition and high prevalence of allergic conditions. The Asia-Pacific region is emerging as a significant market driven by urbanization, growing population, and higher disposable income[1].

Key Players

Major players in the Claritin market include:

• Bayer AG: The primary manufacturer of Claritin RediTabs.
• Sanofi
• Pfizer
• Johnson & Johnson
• Merck[1].

Product Overview

Claritin RediTabs for Juniors 24-Hour

This product provides 24-hour allergy relief for symptoms such as sneezing, runny nose, itchy, watery eyes, and itching of the nose or throat. It is designed for children aged 6 years and older and is easy to take without water, as the tablet melts in the mouth[2].

Active and Inactive Ingredients

The active ingredient is loratadine (10 mg), an antihistamine. Inactive ingredients include anhydrous citric acid, gelatin, mannitol, and mint flavor[2].

Usage and Warnings

The product should be used as directed, with one tablet daily for children aged 6 years and older. Consumers with liver or kidney disease should consult a doctor before use. It is also important to note the potential for allergic reactions and to seek medical help if such reactions occur[2].

Financial Trajectory

Revenue Growth

The projected growth of the Claritin market from USD 0.16 billion in 2023 to USD 0.26 billion by 2031 indicates a robust financial trajectory. This growth is driven by increasing demand for non-drowsy allergy relief medications and the expanding reach of Claritin RediTabs into new markets[1].

Market Share

The market share of Claritin RediTabs is influenced by its strong brand recognition, effective marketing strategies, and the presence of key players like Bayer AG. Despite competition from generic brands, Claritin maintains a significant market share due to its innovative products and wide distribution channels[1].

Regional Performance

North America

North America, particularly the United States and Canada, has a high market penetration for Claritin RediTabs due to strong brand recognition and a high prevalence of allergic conditions. This region is expected to continue driving market growth[1].

Asia-Pacific

The Asia-Pacific region is emerging as a significant market, driven by urbanization, a growing population, and higher disposable income. This region is anticipated to grow at the highest CAGR over the forecast period[3].

Key Takeaways

• The Claritin market, including Claritin RediTabs, is expected to grow at a CAGR of 5.67% from 2023 to 2031.
• Product innovation, lifestyle changes, seasonal demand, and effective marketing are key drivers of market growth.
• Competition from generic brands, market saturation, and regulatory challenges are significant restraints.
• North America and the Asia-Pacific region are crucial for the market's financial trajectory.
• Strong brand recognition and wide distribution channels contribute to Claritin RediTabs' market share.

FAQs

What is the projected market size of Claritin by 2031?

The Claritin market is projected to reach USD 0.26 billion by 2031[1].

What are the key drivers of the Claritin RediTabs market?

Key drivers include product innovation, lifestyle changes, seasonal demand, and effective marketing strategies[1].

Which region is expected to grow at the highest CAGR for the Claritin market?

The Asia-Pacific region is expected to grow at the highest CAGR over the forecast period[3].

What are the main restraints to the Claritin RediTabs market?

Main restraints include competition from generic brands, market saturation, adverse effects, and regulatory challenges[1].

Who are the major players in the Claritin market?

Major players include Bayer AG, Sanofi, Pfizer, Johnson & Johnson, and Merck[1].

Cited Sources

1. Verified Market Research - Claritin Market Size, Share, Growth, Trends & Forecast
2. Claritin - Claritin® RediTabs® for Juniors 24-Hour
3. Mordor Intelligence - Loratadine Market - Size, Analysis, Industry Share & Growth
4. Bayer - Claritin Product Line English Product Monograph
5. Perrigo Company - Perrigo Company Announces Approvals to Market Three New Products